Imunon (NASDAQ: IMNN) regains Nasdaq $1.00 bid price compliance

Rhea-AI Filing Summary

Imunon, Inc. reports that it has received written notice from a Nasdaq Hearings Panel that the company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).

This confirms that Imunon’s common stock, trading under the symbol IMNN, currently meets this key Nasdaq standard and removes the immediate listing risk tied specifically to its share price, as long as the company continues to satisfy applicable Nasdaq rules.

Insights

Equity market structure analyst

Imunon regains compliance with Nasdaq’s $1.00 bid rule, easing delisting pressure.

Imunon discloses that a Nasdaq Hearings Panel has confirmed the company is back in compliance with the $1.00 minimum closing bid price requirement under Listing Rule 5550(a)(2) for the Nasdaq Capital Market. This rule focuses on the stock’s closing price, and regaining compliance means recent trading has met or exceeded that threshold for the period Nasdaq requires.

This development removes the immediate threat of delisting based solely on bid price, which can be a concern for companies trading near $1.00. Continued listing keeps access to Nasdaq’s liquidity and visibility, but ongoing compliance will still depend on maintaining the required bid price and meeting all other Nasdaq standards in future periods.

8-K Event Classification

2 items: 3.01, 9.01

2 items

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice or transferred its listing to a different exchange.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0000749647 0000749647 2025-08-27 2025-08-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 27, 2025

IMUNON, INC.

(Exact name of registrant as specified in its Charter)

Delaware		001-15911		52-1256615
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

997 Lenox Drive, Suite 100, Lawrenceville, NJ		08648-2311
(Address of principal executive offices)		(Zip Code)

(609) 896-9100

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common stock, par value $0.01 per share		IMNN		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On August 27, 2025, Imunon, Inc. (the “Company”) received a written notification from the Nasdaq Hearings Panel indicating that the Company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on the NASDAQ Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated August 28, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	IMUNON, INC.
Dated: August 28, 2025	By:	/s/ Susan Eylward
		Susan Eylward
		General Counsel and Corporate Secretary

FAQ

What did Imunon (IMNN) announce in this 8-K filing?

Imunon reported that it received written notice from a Nasdaq Hearings Panel stating the company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on the Nasdaq Capital Market.

Which specific Nasdaq rule did Imunon regain compliance with?

Imunon regained compliance with the $1.00 minimum closing bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2), referred to as the Minimum Bid Price Requirement.

When did Imunon receive Nasdaq’s notice of regained compliance?

Imunon received the written notification from the Nasdaq Hearings Panel on August 27, 2025, confirming that it had regained compliance with the Minimum Bid Price Requirement.

What does regaining the $1.00 minimum bid price compliance mean for IMNN stock?

Regaining compliance with the $1.00 minimum closing bid price requirement means IMNN currently meets this key Nasdaq Capital Market standard, helping the stock remain listed as long as Imunon continues to satisfy applicable Nasdaq listing rules.

What exhibit did Imunon file with this 8-K?

Imunon included a press release dated August 28, 2025 as Exhibit 99.1 and a Cover Page Interactive Data File as Exhibit 104.